ClinicalTrials.gg
Not yet recruitingNCT06987786COTHAUpdated Oct 16, 2026

Differences in Mechanistic Measures (Oxytocin and Cortisol) of Therapeutic Alliance Between A Talk-Based Therapy and Soft-Tissue Mobilization in Individuals With Chronic Spinal Pain

An interventional study of Massage and Talk-based therapy in Spine, Low Back Pain and Neck Pain, sponsored by Duke University. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Duke University · Not applicable, Interventional, and Treatment

How we know

Updated Oct 16, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 712 studies in Low Back Pain with a site in United States — 100 open to participants now, 126 under way, 3 of them phase 3. Low Back Pain · United States.

Planned enrollment
509th of 623
25 · median 79
Started
2026
with 32 others
No phase
408 of 712
62 open now
Primary completion
2027-06
later than 61 of 125 live
Registered
663rd of 712
by date

Among the 712 studies in Low Back Pain with a site in United States, this one is the 509th largest by planned enrollment of the 623 interventional ones that give a count, is one of 33 that started in 2026, is one of 408 with no phase, reaches primary completion later than 61 of the 125 other live ones, and was the 663rd registered.

Low Back Pain

2,930 studies on the registry are indexed under Low Back Pain; 581 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

100 of the 712 studies in Low Back Pain with a site in United States are open now. Recruiting first, the newest first:

95 more — sign in →

All 100 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 712 studies in Low Back Pain with a site in United States, or all of them as a file.
02

Study summary

The goal of this randomized cross-over mechanistic trial is to compare pre- and post-level cortisol and oxytocin changes in patients with chronic spine pain who receive either a hand's on (massage) or a hand's off (talk-based) approach. The study plans to address two primary aims.

Specific Aim One: Directly compare pre- and post-session oxytocin and cortisol levels across two sessions of massage and talk-based therapy. Hypothesis 1: It is expected that in both treatments, oxytocin will increase and cortisol will decrease, demonstrating no significant between-group differences in hormone levels.

Specific Aim Two: The study plans to compare pre- and post-session oxytocin and cortisol change scores a therapeutic alliance (TA) scale change scores and PROMIS patient-reported outcomes associated with pain, depression, and disability. Hypothesis 2a: It is projected that there will be moderate +/- relationships (R>.4) between the therapeutic alliance change score and oxytocin and cortisol levels, suggesting that the hormones moderately reflect the construct associated with TA. Hypothesis 2b: It is expected that there will be weak (R>.1) +/-relationships between hormone measures and PROMIS pain/disability/depression measures, which reflects similar findings to preliminary work.

Participants will participant in a massage based treatment and a talk-based treatment approach. Participants will also complete patient report outcomes and will receive a total of four salivary swabs.

Read the detailed description

Recruitment at Duke University: Recruitment will follow a well-versed, successful process at Duke University. MaestroCare will be used to identify, recruit, and conduct this research study. Participants will be invited to participate in this study via a MyChart patient portal invitation sent by a clinical research coordinator (CRC). The CRC will screen participants for eligibility via telephone encounter. Prior to obtaining consent, participants will be screened for medical conditions that may influence hormone levels during the study (e.g., Cushing's Syndrome, Addison's Disease, etc.), use of medications (e.g., steroids, antidepressants, or hormonal treatments) that could influence the results, and exclude participants if necessary, and previously diagnosed conditions or factors known to affect cortisol or oxytocin levels, such as chronic stress disorders, hormonal imbalances, or pregnancy. After obtaining consent and prior to treatment, the study will screen for potential STM contraindications or other clinical safety considerations (i.e., infection, skin lesions, etc) using a limited systems-screening to rule out pertinent clinical contraindications to STM (e.g., radiculopathy, fracture, etc.).

Participants: Individuals with CSP (3 months or greater), who are 18 years of age and older and who experience persistent pain of ≥3 on a 10-point scale for the majority of days during the previous 3-months will be eligible for the study. The study operationally defines chronic pain using the International Association of the Study of Pain (IASP) pragmatic criteria of pain lasting for 3 months or more that cannot be attributed to another diagnosis or condition.

Variables: In addition to pertinent demographics and patient characteristics, the study will capture baseline PROMIS pain interference, pain intensity, depression, and physical function values. Onsite, to improve the likelihood that hormone related changes are not influenced by external factors, the study will capture a Perceived Stress Scale (PSS), which measures subjective stress levels, State-Trait Anxiety Inventory (STAI), which assesses temporary and long-term anxiety states, blood pressure and pulse prior to each visit. For the PSS, a score of 27 or above is typically considered high. For the STAI, a score above 60 is often considered high, signaling significant anxiety. If individuals score high in either measure, the participants will be rescheduled. Those with Blood pressure: ≥140/90 mmHg and a heart rate >100bpm will be asked to reschedule.

The study's primary variables of interest in the study involve cortisol and oxytocin levels. The study will capture 525 μL salivary concentrations of oxytocin and cortisol through a SalivaBio Oral Swab (SOS) Method. Testing will be completed with Salimetrics Assay Kits. The study will also capture the self-report WAI short-form and the PROMIS pain interference, pain intensity, and physical function measures at baseline and after completion of both visits.

Interventions: After describing the study design and purpose, participants will be randomized into a single treatment of STM-first or a single treatment of ER-first. All treatments will be provided by Dr. Cook, a licensed physical therapist with 35 years of clinical experience and fellowship-level training in STM (e.g., manual therapies) and a 2.5-year post-professional, certification-level training in chronic pain management/psychologically informed practice. A designated clinical research coordinator (CRC) and Dr. Cook will be responsible for screening of each applicant to ensure the participants are appropriate and safe for study inclusion.

03

Conditions studied

  • Spine
  • Low Back Pain
  • Neck Pain

Keywords

  • Oxytocin
  • Cortisol
  • spinal pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals with chronic spine pain (3 months or greater) (and);
  • who are 18 years of age and older (and)
  • who experience persistent pain of ≥3 on a 10-point scale for the majority of days during the previous 3-months

(The study operationally defines chronic pain using the International Association of the Study of Pain (IASP) pragmatic criteria of pain lasting for 3 months or more that cannot be attributed to another diagnosis or condition).

-

Exclusion criteria

Exclusion Criteria include:

  • Participants with medical conditions that may influence hormone levels during the study (e.g., Cushing's Syndrome, Addison's Disease, etc.) (or),
  • Use of medications (e.g., , antidepressants, or hormonal treatments) that could influence the results (or)
  • Previously diagnosed conditions or factors known to affect cortisol or oxytocin levels, such as chronic stress disorders, hormonal imbalances, or pregnancy.

(After obtaining consent and prior to treatment), the study will screen for potential massage or other clinical safety considerations and will exclude if:

  • participants have infection, skin lesions, (or)
  • Fractures in the region of the massage
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Massage, then talk-based therapy

    Subjects will be randomized to receive massage for one session, then will receive talk-based therapy after a two week washout period.

    Other: Massage · Other: Talk-based therapy

  • Experimental
    Talk-based therapy, then massage

    Subjects will be randomized to receive talk-based therapy first, then after a 2 week wash out period will receive a massage threatment

    Other: Massage · Other: Talk-based therapy

Interventions

  • OtherMassage

    Soft tissue mobilization (STM), also known as massage, is a form of manual therapy. STM consists of many different categories of treatment, but all involve a "hand's on" application. During the session, the Dr. Cook will use techniques such as kneading, stretching, and deep tissue manipulation to target the affected areas. The total time of application will be 30 minutes. This "hands-on" approach is theorized to reduce muscle tension, improve blood circulation, and promote relaxation. STM stimulates the release of endorphins and serotonin, which are natural painkillers and mood enhancers.

  • OtherTalk-based therapy

    Talk based therapy includes an innovative, evidence-based psychosocial therapy designed to provide rapid and effective pain management for individuals suffering from chronic pain. This single-session, intervention equips patients with essential pain relief skills through a combination of cognitive behavioral therapy (CBT) techniques, mindfulness principles, and pain neuroscience education. The program focuses on teaching patients how to identify and reframe distressing thoughts, practice relaxation techniques, and develop personalized pain management plans.

06

What researchers measure

Primary outcomes

  1. Cortisol changes

    The study will capture 525 μL salivary concentrations cortisol through a SalivaBio Oral Swab (SOS) Method. Testing will be completed with Salimetrics Assay Kits.

    Time frame: Day 1 and day 15

  2. Oxytocin changes

    The study will capture 525 μL salivary concentrations of oxytocin through a SalivaBio Oral Swab (SOS) Method. Testing will be completed with Salimetrics Assay Kits.

    Time frame: Day 1 and day 15

Secondary outcomes

  1. Therapeutic alliance

    Working Alliance Inventory (WAI) short-form. The Working Alliance Inventory (WAI) measures three important aspects of the therapeutic alliance: 1. Agreement about the therapeutic tasks, 2. Agreement about the therapeutic goals, and 3. The affective bond between clinician and client. The WAI short-form is scored by adding up individual item responses, which are rated on a 5-point Likert scale (1=rarely or never to 5=always). The Working Alliance Inventory-Short (WAI-S) has a total score ranging from 12 to 84. A higher score indicates a stronger working alliance between a patient and therapist.

    Time frame: Day 1 and day 15

  2. PROMIS pain interference

    The PROMIS Pain Interference (PROMIS-PI) measure assesses the extent to which pain affects a person's daily life, specifically their ability to engage in social, cognitive, emotional, physical, and recreational activities. It's a widely used instrument within the PROMIS (Patient-Reported Outcomes Measurement Information System) initiative, a set of tools for measuring patient-reported outcomes in various health conditions. The PROMIS Pain Interference (PI) scale, particularly the 4-item short form (4a), measures how much pain interferes with an individual's activities over the past 7 days. Each question is answered on a 5-point scale (1=never to 5=almost always), and the total score is calculated by summing the individual item scores. For the 4-item short form, the total raw score range is 4 to 20, with higher scores indicating greater pain interference. PROMIS also uses a T-score metric, where the mean is 50 and the standard deviation is 10.

    Time frame: Day 1 and day 15

  3. PROMIS Pain intensity

    The PROMIS Pain Intensity measure assesses how much pain a person is experiencing. It uses a numeric rating scale (NRS) where individuals rate their pain on a scale from 0 (no pain) to 10 (worst possible pain). The PROMIS Pain Intensity measure is part of the broader Patient-Reported Outcomes Measurement Information System (PROMIS) initiative, which aims to develop standardized, reliable, and valid tools for measuring patient-reported outcomes.

    Time frame: Day 1 and day 15

  4. PROMIS Depression

    The PROMIS Depression measure is a tool used to assess depression, specifically focusing on affective and cognitive symptoms like sadness, guilt, and self-criticism. It's part of the Patient-Reported Outcomes Measurement Information System (PROMIS), a collection of measures designed to evaluate patient-reported outcomes. PROMIS Depression 4 scale measures depression severity using a four-item questionnaire. Each item is rated on a scale, and the total score is the sum of these ratings, ranging from 4 to 20. Higher scores indicate more severe depression. It's important to note that PROMIS scales, including the 4-item depression scale, also use a T-score system, which is a standardized score with a mean of 50 and a standard deviation of 10.

    Time frame: Day 1 and day 15

  5. PROMIS physical function

    The PROMIS Physical Function 4 scale is measured using a series of questions assessing a person's ability to perform various physical tasks, with responses scored on a 5-point Likert scale. The raw score from these responses is then converted to a standardized T-score on a scale of 0 to 100, with a mean of 50 and a standard deviation of 10. The total score is the final T-score.

    Time frame: Day 1 and day 15

07

Study locations

1 site
  • CORE 2200 West Main Street
    Durham, North Carolina 27705, United States
    • Chad E Cook, PT PhD · Contactchad.cook@duke.edu · 9196848905
    • Chad E Cook, professor, PT PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jun 2027, 6 months later.

Of 1,234 non-industry interventional studies with no phase under Low Back Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 26. This study's planned 6 months is below that.

Counting every sponsor, half of 1,290 studies reached it within 11 months; a quarter within 5 and three quarters within 27.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: start Jun 2026 → Dec 2026, primary completion Nov 2026 → Jun 2027 and completion Nov 2026 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2025
First posted
May 23, 2025
StartEst.
Dec 1, 2026was Jun 2026
Primary completionEst.
Jun 30, 2027was Nov 2026
CompletionEst.
Oct 30, 2027was Nov 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 1, 2026→Dec 1, 2026
Oct 16, 2026
Primary completion
Nov 30, 2026→Jun 30, 2027
Oct 16, 2026
Study completion
Nov 30, 2026→Oct 30, 2027
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Start date Jun 1, 2026→Dec 1, 2026
    Primary completion Nov 30, 2026→Jun 30, 2027
    Study completion Nov 30, 2026→Oct 30, 2027
    + 1 other change: contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06987786
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
May 23, 2025
Start date
Dec 1, 2026 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
Oct 30, 2027 (estimated)
Last update
Oct 16, 2026

Study contacts

Chad E Cook, principal investigator, PT, PHD
Contact
chad.cook@duke.edu
19196848905
Chad E Cook
principal investigator · Duke University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion